Session: MON 327-337-Neuroendocrine Tumors
Poster Board MON-328
Objective: To describe the main features of patients diagnosed with CP admitted in our center between years 2000 and 2012.
Material and Methods: Descriptive retrospective study. We performed a systematic search in our clinical database between years 2000 and 2012, including all patients with postoperative diagnosis of CP. Total sample: n=58.
Results: Our sample is composed by n=20 (54.2%) children, n=38 (45.8%) adults; n=30 males (51.7% of total sample, 62.5% children, 50% adults); median of age at diagnosis 7 years ( children), 43 yr (adults). Main neurological manifestations at diagnosis were visual impairment (66.7% children, 75% adults) and headache (50% children, 70.6% adults), as well as intracranial hypertension (50% children, 33.3% adults); the most frequent endocrine abnormalities were diabetes insipidus (50% children, 16.7% adults), menstrual disorders and growth impairment. The preferred surgical approach was an open technique. Postoperative sequelae were present in 97.9% of total patients (100% children, 96.7% adults), usually panhypopituitarism (92.3% children, 89.3% adults), diabetes insipidus (81.8% children, 76.9% adults) and obesity/polyphagia (71.4 % children, 40% adults), visual impairment (72.7% children, 63.6% adults), epilepsy (37.5% children, 25% adults), hydrocephalus (30% children, 30.8% adults), CSF leakage (45.5% children, 10.5% adults), and psychiatric disorders (80% children, 26.3% adults). In 47.7% of cases, external adjuvant treatment was applied, mainly radiotherapy (100% conventional radiotherapy in children, while in adults 67% was stereotactic vs. 33% conventional). The disease relapsed in 46.7% of total patients (69.2% children, 37.9% adults) requiring re-intervention approximately 2 years after initial surgery. Mortality rate is up to 20% (n=12).
Conclusions: Our results are consistent with currently available evidence about CP, as we observe high rates of morbidity and mortality. These findings support the need of a multidisciplinary approach to this disease in order to minimize the devastating consequences of both the disease and its treatment.
Nothing to Disclose: EMV, AJM, MED, EJG, AA, MNG, FJM, JMP, BG, AL, AMS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters